Analyst Price Targets — CVE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 2, 2026 12:17 pm | — | Goldman Sachs | $22.00 | $19.72 | TheFly | Cenovus Energy price target raised to $22 from $20 at Goldman Sachs |
| January 2, 2026 9:29 am | Neil Mehta | Goldman Sachs | $20.00 | $16.92 | TheFly | Cenovus Energy reinstated with a Buy at Goldman Sachs |
| November 17, 2025 12:13 pm | — | BMO Capital | $29.00 | $18.13 | TheFly | Cenovus Energy resumed with an Outperform at BMO Capital |
| November 17, 2025 12:08 pm | — | RBC Capital | $32.00 | $18.13 | TheFly | Cenovus Energy price target raised to $32 from $30 at RBC Capital |
| October 4, 2024 8:41 am | Randy Ollenberger | BMO Capital | $31.00 | $17.84 | TheFly | Cenovus Energy price target lowered to $31 from $33 at BMO Capital |
Latest News for CVE
111 Capital trimmed its stake in Cenovus Energy Inc (NYSE: CVE) (TSE: CVE) by 30.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 51,658 shares of the oil and gas company's stock after selling 22,883 shares during the
PSX's diversified model may outshine CVE as soft oil prices pressure upstream earnings and reshape energy investment appeal.
CALGARY, Alberta, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cenovus Energy Inc. (TSX: CVE) (NYSE: CVE) today announced it will exercise its right to redeem its 2.577% Series 1 Preferred Shares (the “Series 1 Preferred Shares”) and its 3.948% Series 2 Preferred Shares (the “Series 2 Preferred Shares”, collectively, the “Series 1 & 2 Preferred Shares”) on March 31, 2026 (the “Redemption”). All of the Series 1 & 2 Preferred…
CVE posts Q4 EPS beat on higher oil sands output as upstream production jumps, despite weaker revenues and rising transport costs.
Cenovus Energy Inc. (TSE: CVE - Get Free Report) (NYSE: CVE) has earned a consensus recommendation of "Buy" from the twelve brokerages that are presently covering the stock, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold recommendation, eight have assigned a buy recommendation and two have assigned a strong buy recommendation to
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for CVE.
Senate Trading
No Senate trades found for CVE.
U.S. House Trading
No House trades found for CVE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.